Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 18/20 | 1.00 |
| ▸ | BRDT | Q58F21 | 3/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 3/20 | 1.00 |
| ▸ | PIK3CB | P42338 | 3/20 | 1.00 |
| ▸ | BRD4 | O60885 | 2/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 2/20 | 1.00 |
| ▸ | MTOR | P42345 | 2/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | PDE2A | O00408 | 1/20 | 0.67 |
| ▸ | PIK3C2A | O00443 | 1/20 | 0.67 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.67 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.67 |
| ▸ | PDE5A | O76074 | 1/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30203800 | 1.00 | PRKDC (1.00) | PRKDCBRDTPIK3CDPIK3CBBRD4 | |
| SCHEMBL29373835 | 1.00 | PRKDC (1.00) | PRKDCBRDTPIK3CDPIK3CBBRD4 | |
| SCHEMBL29380743 | 1.00 | PRKDC (1.00) | PRKDCBRDTPIK3CDPIK3CBBRD4 | |
| SCHEMBL14500127 | 0.90 | PRKDC (0.82) | PRKDCBRDTPIK3CDPIK3CBBRD4 | |
| SCHEMBL3716173 | 0.89 | PRKDC (0.80) | PRKDCBRDTPIK3CDPIK3CBBRD4 | |
| SCHEMBL3717990 | 0.89 | PRKDC (0.80) | PRKDCBRDTPIK3CDPIK3CBBRD4 | |
| SCHEMBL3291675 | 0.88 | PRKDC (0.78) | PRKDCBRDTPIK3CDPIK3CBBRD4 | |
| SCHEMBL1942262 | 0.87 | PRKDC (0.77) | PRKDCBRDTPIK3CDPIK3CBBRD4 | |
| SCHEMBL3644680 | 0.87 | PRKDC (0.77) | PRKDCBRDTPIK3CDPIK3CBBRD4 | |
| SCHEMBL3715022 | 0.87 | PRKDC (0.77) | PRKDCBRDTPIK3CDPIK3CBBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11833225-B2 | Methods and compositions for efficient gene deletion | CRISPR THERAPEUTICS AG (CH) | 2023-12-05 | — | — | US | claimed |
| EP-3802826-A1 | METHODS AND COMPOSITIONS FOR EFFICIENT GENE DELETION | CRISPR Therapeutics AG (CH) | 2021-04-14 | — | — | EP | claimed |
| US-20200299729-A1 | METHODS FOR IMPROVED HOMOLOGOUS RECOMBINATION AND COMPOSITIONS THEREOF | Life Technologies Corporation | 2020-09-24 | — | — | US | claimed |
| EP-3679144-A1 | METHODS FOR IMPROVED HOMOLOGOUS RECOMBINATION AND COMPOSITIONS THEREOF | Life Technologies Corporation (US) | 2020-07-15 | — | — | EP | claimed |
| EP-3632208-A1 | CELL STABILIZATION | Biomatrica, INC. (US) | 2020-04-08 | — | — | EP | claimed |
| WO-2019051316-A1 | METHODS FOR IMPROVED HOMOLOGOUS RECOMBINATION AND COMPOSITIONS THEREOF | Life Technologies Corporation (US) | 2019-03-14 | — | — | WO | claimed |
| US-20160135446-A1 | CELL STABILIZATION | MXCGLOBAL INC. | 2016-05-19 | — | — | US | claimed |
| EP-3007556-A2 | CELL STABILIZATION | Biomatrica, INC. (US) | 2016-04-20 | — | — | EP | claimed |
| WO-2015002729-A2 | CELL STABILIZATION | BIOMATRICA, INC. (US) | 2015-01-08 | — | — | WO | claimed |
| WO-2013029116-A1 | METHOD FOR PREDICTING TREATMENT RESPONSIVENESS | MONASH UNIVERSITY (AU) | 2013-03-07 | — | — | WO | claimed |
| US-20090035394-A1 | USE OF DNA-PK INHIBITION TO SENSITISE ATM DEFICIENT CANCERS TO DNA-DAMAGING CANCER THERAPIES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-02-05 | — | — | US | claimed |
| EP-1895997-A2 | USE OF DNA-PK INHIBITION TO SENSITISE ATM DEFICIENT CANCERS TO DNA-DAMAGING CANCER THERAPIES | Kudos Pharmaceuticals Ltd (GB) | 2008-03-12 | — | — | EP | claimed |
| WO-2006126010-A2 | USE OF DNA-PK INHIBITION TO SENSITISE ATM DEFICIENT CANCERS TO DNA-DAMAGING CANCER THERAPIES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-11-30 | — | — | WO | claimed |
| US-12612650-B2 | Methods for improved homologous recombination and compositions thereof | Life Technologies Corporation (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-12491191-B2 | Inhibition of interaction between OCT4 and MAPKAPK2 or DNA-PKcs to regulate c-MYC in cancer | TEXAS TECH UNIVERSITY SYSTEM (US) | 2025-12-09 | — | — | US | disclosed |
| WO-2008009934-A1 | SYNTHESIS OF 2-AMINO-SUBSTITUTED 4-OXO-4H-CHROMEN-8.YL-TRIFLUORO-METHANESULFONIC ACID ESTERS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-01-24 | — | — | WO | disclosed |
| US-20070238731-A1 | Dna-Pk Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2007-10-11 | — | — | US | disclosed |
| US-20070238731-A1 | Dna-Pk Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2007-10-11 | — | — | US | disclosed |
| WO-2006126010-A2 | USE OF DNA-PK INHIBITION TO SENSITISE ATM DEFICIENT CANCERS TO DNA-DAMAGING CANCER THERAPIES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160135446-A1 | CELL STABILIZATION | CALR, CALU, TREH | PRKDC 1938/4885BRDT 4502/4885PIK3CD 2885/4885 |
| US-12612650-B2 | Methods for improved homologous recombination and compositions thereof | RPRD2, ZFR, ZMYND8 | PRKDC 397/4885BRDT 52/4885PIK3CD 3565/4885 |
| US-20090035394-A1 | USE OF DNA-PK INHIBITION TO SENSITISE ATM DEFICIENT CANCERS TO DNA-DAMAGING CANCER THERAPIES | ATM, CHEK2, DCK | PRKDC 37/4885BRDT 358/4885PIK3CD 816/4885 |
| US-12491191-B2 | Inhibition of interaction between OCT4 and MAPKAPK2 or DNA-PKcs to regulate c-MYC in cancer | MYCBP, MYC, MAPKAPK2 | PRKDC 4/4885BRDT 464/4885PIK3CD 1309/4885 |
| US-20070238731-A1 | Dna-Pk Inhibitors | XRCC6, XRCC5, POLK | PRKDC 317/4885BRDT 997/4885PIK3CD 1808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.